These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 27165535)

  • 1. The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in vitro model for therapeutic angioedema agents.
    Jean M; Raghavan A; Charles ML; Robbins MS; Wagner E; Rivard GÉ; Charest-Morin X; Marceau F
    Life Sci; 2016 Jun; 155():180-8. PubMed ID: 27165535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors.
    Charest-Morin X; Raghavan A; Charles ML; Kolodka T; Bouthillier J; Jean M; Robbins MS; Marceau F
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00119. PubMed ID: 26038695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of vasoactive peptide bradykinin from human umbilical vein endothelium-bound high molecular weight kininogen by plasma kallikrein.
    Nishikawa K; Shibayama Y; Kuna P; Calcaterra E; Kaplan AP; Reddigari SR
    Blood; 1992 Oct; 80(8):1980-8. PubMed ID: 1391955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
    Charest-Morin X; Hébert J; Rivard GÉ; Bonnefoy A; Wagner E; Marceau F
    Front Immunol; 2018; 9():2183. PubMed ID: 30333824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Modeling of Bradykinin-Mediated Angioedema States.
    Marceau F; Bachelard H; Charest-Morin X; Hébert J; Rivard GE
    Pharmaceuticals (Basel); 2020 Aug; 13(9):. PubMed ID: 32824891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
    Kaplan AP; Joseph K
    Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor XII-independent activation of the bradykinin-forming cascade: Implications for the pathogenesis of hereditary angioedema types I and II.
    Joseph K; Tholanikunnel BG; Bygum A; Ghebrehiwet B; Kaplan AP
    J Allergy Clin Immunol; 2013 Aug; 132(2):470-5. PubMed ID: 23672780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bradykinin release from high molecular weight kininogen and increase in plasma kallikrein-like activity following sensory stimulation by food in the rat.
    Rothschild AM; Gomes EL; Fortunato IC
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):483-8. PubMed ID: 9826071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.
    Charignon D; Späth P; Martin L; Drouet C
    Expert Opin Pharmacother; 2012 Oct; 13(15):2233-47. PubMed ID: 22970904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue kallikrein actions at the rabbit natural or recombinant kinin B2 receptors.
    Houle S; Molinaro G; Adam A; Marceau F
    Hypertension; 2003 Mar; 41(3):611-7. PubMed ID: 12623967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Robust Bioassay of the Human Bradykinin B
    Marceau F; Bachelard H
    Pharmaceuticals (Basel); 2021 Feb; 14(3):. PubMed ID: 33668382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-derived proteinase 3 induces kallikrein-independent release of a novel vasoactive kinin.
    Kahn R; Hellmark T; Leeb-Lundberg LM; Akbari N; Todiras M; Olofsson T; Wieslander J; Christensson A; Westman K; Bader M; Müller-Esterl W; Karpman D
    J Immunol; 2009 Jun; 182(12):7906-15. PubMed ID: 19494315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bradykinin-mediated diseases.
    Kaplan AP
    Chem Immunol Allergy; 2014; 100():140-7. PubMed ID: 24925394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase-activated latent ligands of the histamine receptor-1.
    Gera L; Roy C; Charest-Morin X; Marceau F
    Int Immunopharmacol; 2013 Nov; 17(3):677-83. PubMed ID: 24016859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin.
    Kleniewski J; Blankenship DT; Cardin AD; Donaldson V
    J Lab Clin Med; 1992 Jul; 120(1):129-39. PubMed ID: 1535355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of allelic polymorphism of the B(1) and B(2) receptor genes on the contractile responses of the human umbilical vein to kinins.
    Houle S; Landry M; Audet R; Bouthillier J; Bachvarov DR; Marceau F
    J Pharmacol Exp Ther; 2000 Jul; 294(1):45-51. PubMed ID: 10871294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
    Molinaro G; Gervais N; Adam A
    Stroke; 2002 Jun; 33(6):1712-6. PubMed ID: 12053016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased fibrinolysis-induced bradykinin formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors.
    Marceau F; Bachelard H; Rivard GÉ; Hébert J
    BMC Res Notes; 2019 May; 12(1):291. PubMed ID: 31133046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
    Charlesworth MC; Young CY; Miller VM; Tindall DJ
    J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A role of kallikrein-kinin system in gut diseases].
    Zelawski W; Witalińska-Labuzek J; Stadnicki A
    Wiad Lek; 2005; 58(5-6):331-4. PubMed ID: 16238127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.